---
title: 'Director, Quality Assurance at Nurix'
canonical: 'https://feeny.ai/job/director-quality-assurance-nurix-brisbane-3g1nz641gtdv'
type: 'job'
last_seen: '2026-10-29'
---

# Director, Quality Assurance at Nurix

- **Company:** Nurix
- **Location:** Brisbane, CA
- **Posted:** 2026-10-23
- **Last confirmed live:** 2026-10-29
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8910420002

## Job description

Director, Quality Assurance

Lead GMP quality assurance for Nurix's small molecule CMC programs and serve as the primary quality interface with our CDMO partners. You'll be accountable for the quality and timely supply of clinical materials and for inspection readiness, while building and mentoring the QA team as we advance through late-stage development toward commercialization.

Position Description

The Opportunity

- Report to the Senior Vice President, Quality, in a high-visibility role with direct accountability across Quality, CMC, Regulatory Affairs, and external manufacturing partners; operate both strategically and hands-on in a dynamic clinical-stage environment
- Provide strategic quality leadership for CMC development programs, ensuring GMP compliance with FDA, ex-US regulatory authorities, and ICH guidelines across drug substance and drug product development
- Serve as the primary quality interface with CDMOs and contract laboratories, overseeing quality operations including review and approval of deviations, investigations, batch records, lot disposition, technical protocols and reports, methods, and specifications
- Lead and develop a team of Quality Assurance professionals; set clear performance expectations, mentor, and build organizational capability to support pipeline advancement and commercialization readiness
- Drive timely identification, investigation, and resolution of quality events and deviations, and oversee CAPA execution and effectiveness verification to prevent recurrence
- Support the change control process, ensuring changes that affect manufacturing, testing, and regulatory filings are captured, and escalate issues with broad cross-functional impact
- Support regulatory inspection readiness; serve as a quality representative during FDA, EMA, and other agency inspections and develop observation responses
- Contribute to CMC sections of regulatory filings (INDs, NDAs/BLAs) in partnership with Regulatory Affairs, and partner with CMC and Regulatory Affairs to align quality deliverables with pipeline milestones and program timelines
- Support implementation and optimization of the electronic quality management system (eQMS) platform and contribute to system improvement initiatives
- Maintain current knowledge of evolving regulatory expectations and industry standards, and translate requirements into practical operational guidance for the organization

## What You’ll Bring

- Bachelor's degree in chemistry, pharmaceutical sciences, life sciences, or a related field
- 12+ years of progressive Quality Assurance experience in the pharmaceutical or biopharmaceutical industry, with experience in a formal leadership role
- Deep technical expertise in GMP requirements for small molecule drug substances and drug products across clinical development stages
- Demonstrated experience managing CDMO relationships and overseeing quality operations at contract manufacturing and laboratory organizations
- Thorough knowledge of FDA regulations (21 CFR Parts 210/211), ICH guidelines (Q7, Q8, Q9, Q10, Q11), and EudraLex Volume 4 (GMP), and their practical application to CMC development
- Proven track record managing quality events, deviations, CAPA programs, and change control in a clinical or commercial pharmaceutical setting
- Experience supporting or leading regulatory agency inspections (FDA, EMA, or equivalent); experience as lead QA representative during pre-approval inspections preferred
- Demonstrated ability to lead, develop, and motivate Quality Assurance teams in a fast-paced, ambiguous, clinical-stage environment
- Excellent project management skills, with the ability to manage multiple high-priority deliverables simultaneously
- Strong verbal and written communication skills; able to present complex quality and compliance topics clearly to diverse stakeholders, including executive leadership
- Willingness to travel to CDMO and laboratory sites domestically and internationally, as needed
- Preferred: experience in a clinical-stage biotech environment scaling quality operations through late-stage development and toward commercialization
- Preferred: experience with electronic QMS platforms (e.g., Veeva Vault) and document management systems
- Preferred: expertise in both development-phase and pre-commercial-phase quality assurance standards and expectations

Location:        Onsite – Brisbane, CA

Salary Range:  $228,100 - $252,000

The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.

Fit with Nurix Culture and Values

- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view

## About Nurix Therapeutics

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Senior/Principal Scientist, Medicinal Chemistry](https://feeny.ai/job/senior-principal-scientist-medicinal-chemistry-nurix-brisbane-sk240f67bwms) — Brisbane, CA
- [Scientist I, Bioanalytical](https://feeny.ai/job/scientist-i-bioanalytical-nurix-brisbane-tns4szvd5c07) — Brisbane, CA
- [Senior Research Associate, Preclinical Pharmacology](https://feeny.ai/job/senior-research-associate-preclinical-pharmacology-nurix-brisbane-whtmqmhser7g) — Brisbane, CA
- [Senior Scientist, Medicinal Chemistry](https://feeny.ai/job/senior-scientist-medicinal-chemistry-nurix-the-woodlands-y4nmgjxktsm5) — The Woodlands, TX
- [Scientist I, Medicinal Chemistry](https://feeny.ai/job/scientist-i-medicinal-chemistry-nurix-the-woodlands-bxgy2c1m60vz) — The Woodlands, TX
- [Senior Director, Head of Pharmacovigilance Operations](https://feeny.ai/job/senior-director-head-of-pharmacovigilance-operations-nurix-brisbane-qvx5sf5gc0cv) — Brisbane, CA
- [Senior Manager / Associate Director, Regulatory Affairs CMC (Small Molecules)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-cmc-small-molecules-nurix-pp3fh8jc68k1) — Brisbane, CA
- [Administrative Assistant, Clinical Development (Contract)](https://feeny.ai/job/administrative-assistant-clinical-development-contract-nurix-brisbane-6rnsp2fj2vte) — Brisbane, CA
- [Administrative Assistant, CMC (Contract)](https://feeny.ai/job/administrative-assistant-cmc-contract-nurix-brisbane-cgkssyzb35sq) — Brisbane, CA
- [Associate Director, Regulatory & Medical Writing](https://feeny.ai/job/associate-director-regulatory-medical-writing-nurix-brisbane-2ges8w25nvka) — Brisbane, CA